Literature DB >> 2291871

The pharmacokinetics and activation of proguanil in man: consequences of variability in drug metabolism.

N A Helsby1, S A Ward, G Edwards, R E Howells, A M Breckenridge.   

Abstract

1. Based on the ratio of drug to active metabolite excreted in urine approximately 3% of a healthy Caucasian population showed a reduced ability to convert proguanil to cycloguanil. 2. Pharmacokinetic analysis showed that this observation resulted from a reduced oral clearance of proguanil in these individuals (245, 534 and 552 ml min-1) compared with the rest of the population (858 +/- 482 ml min-1). 3. Peak plasma concentrations of active metabolite were significantly lower in these subjects (54.2, 26.8 and 51.7 ng ml-1) compared with the rest of the population (141 +/- 45.2 ng ml-1). 4. The observed variability may result from the polymorphic metabolism of proguanil in man.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2291871      PMCID: PMC1368250          DOI: 10.1111/j.1365-2125.1990.tb03818.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  9 in total

1.  Inter-subject variability in the metabolism of proguanil to the active metabolite cycloguanil in man.

Authors:  S A Ward; W M Watkins; E Mberu; J E Saunders; D K Koech; H M Gilles; R E Howells; A M Breckenridge
Journal:  Br J Clin Pharmacol       Date:  1989-06       Impact factor: 4.335

2.  Determination of proguanil and its metabolites cycloguanil and 4-chlorophenylbiguanide in plasma, whole blood and urine by high-performance liquid chromatography.

Authors:  R B Taylor; R R Moody; N A Ochekpe
Journal:  J Chromatogr       Date:  1987-05-15

3.  Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.

Authors:  M Eichelbaum; N Spannbrucker; B Steincke; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1979-09       Impact factor: 2.953

4.  A preliminary pharmacokinetic study of the antimalarial drugs, proguanil and chlorproguanil.

Authors:  W M Watkins; J D Chulay; D G Sixsmith; H C Spencer; R E Howells
Journal:  J Pharm Pharmacol       Date:  1987-04       Impact factor: 3.765

5.  Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man.

Authors:  A Küpfer; R Preisig
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

6.  Single dose pharmacokinetics of proguanil and its metabolites in healthy subjects.

Authors:  Y Wattanagoon; R B Taylor; R R Moody; N A Ochekpe; S Looareesuwan; N J White
Journal:  Br J Clin Pharmacol       Date:  1987-12       Impact factor: 4.335

7.  Polymorphic hydroxylation of Debrisoquine in man.

Authors:  A Mahgoub; J R Idle; L G Dring; R Lancaster; R L Smith
Journal:  Lancet       Date:  1977-09-17       Impact factor: 79.321

8.  Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism.

Authors:  P J Wedlund; W S Aslanian; C B McAllister; G R Wilkinson; R A Branch
Journal:  Clin Pharmacol Ther       Date:  1984-12       Impact factor: 6.875

9.  Characterization and inhibition of mephenytoin 4-hydroxylase activity in human liver microsomes.

Authors:  S D Hall; F P Guengerich; R A Branch; G R Wilkinson
Journal:  J Pharmacol Exp Ther       Date:  1987-01       Impact factor: 4.030

  9 in total
  19 in total

1.  Lengthy antimalarial activity of atovaquone in human plasma following atovaquone-proguanil administration.

Authors:  M D Edstein; B M Kotecka; K L Anderson; D J Pombo; D E Kyle; K H Rieckmann; M F Good
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

2.  The pharmacokinetics and pharmacodynamics of atovaquone and proguanil for the treatment of uncomplicated falciparum malaria in third-trimester pregnant women.

Authors:  K Na-Bangchang; C Manyando; R Ruengweerayut; D Kioy; M Mulenga; G B Miller; J Konsil
Journal:  Eur J Clin Pharmacol       Date:  2005-07-23       Impact factor: 2.953

Review 3.  Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach.

Authors:  Gail D Anderson
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

4.  Evidence for the polymorphic oxidation of debrisoquine and proguanil in a Khmer (Cambodian) population.

Authors:  S Wanwimolruk; M R Thou; D J Woods
Journal:  Br J Clin Pharmacol       Date:  1995-08       Impact factor: 4.335

5.  Single dose pharmacokinetics of proguanil and its metabolites in pregnancy.

Authors:  J Wangboonskul; N J White; F Nosten; F ter Kuile; R R Moody; R B Taylor
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 6.  Genetically determined adverse drug reactions involving metabolism.

Authors:  M S Lennard
Journal:  Drug Saf       Date:  1993-07       Impact factor: 5.606

7.  Oxidative activation of proguanil and dapsone acetylation in Thai soldiers.

Authors:  M D Edstein; G D Shanks; P Teja-Isavadharm; K H Rieckmann; H K Webster
Journal:  Br J Clin Pharmacol       Date:  1994-01       Impact factor: 4.335

Review 8.  Clinical significance of the cytochrome P450 2C19 genetic polymorphism.

Authors:  Zeruesenay Desta; Xiaojiong Zhao; Jae-Gook Shin; David A Flockhart
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

9.  The multiple dose pharmacokinetics of proguanil.

Authors:  N A Helsby; G Edwards; A M Breckenridge; S A Ward
Journal:  Br J Clin Pharmacol       Date:  1993-06       Impact factor: 4.335

10.  Relationship between proguanil metabolic ratio and CYP2C19 genotype in a Caucasian population.

Authors:  J M Hoskins; G M Shenfield; A S Gross
Journal:  Br J Clin Pharmacol       Date:  1998-11       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.